Quantcast

Latest Epidermal growth factor receptor Stories

2011-09-26 13:12:21

Effects of a particularly devastating human kidney disease may be blunted by making a certain cellular protein receptor much less receptive, according to new research by scientists from North Carolina State University and a number of French universities and hospitals. The findings take a major step toward suggesting a beneficial treatment for rapidly progressive glomerulonephritis (RPGN), a rare but debilitating kidney disease that causes renal failure and death in humans. In a paper...

2011-09-20 05:54:47

(Ivanhoe Newswire) — Glioblastoma is the most common brain malignancy and one of the most lethal of all cancers, killing most victims within 12-15 months of diagnosis. It is also one of the most chemotherapy-radiation resistant cancers. Researchers found that by blocking brain cancer cells from getting large amounts of cholesterol they could provide a new strategy to battle glioblastoma, according to this study. The study, done in cells lines, mouse models and analysis of tissue from...

2011-09-15 20:41:07

Blocking the uptake of large amounts of cholesterol into brain cancer cells could provide a new strategy to battle glioblastoma, one of the most deadly malignancies, researchers at UCLA's Jonsson Comprehensive Cancer Center have found. The study, done in cells lines, mouse models and analysis of tissue from brain cancer patients, uncovered a novel mechanism by which the most commonly activated oncogene, the mutated epidermal growth factor receptor (EGFR), overcomes normal cell regulatory...

2011-09-12 05:15:06

(Ivanhoe Newswire) -- Scientists have found a new way to heighten or restore the potency of a widely-used cancer drug. The drug cetuximab is an antibody that interferes with cancer cell growth by blocking a structure known as the epidermal growth factor receptor (EGFR). The drug is often effective for patients with colorectal cancer and squamous cell cancer of the head and neck, but the benefits typically do no last longer than one year. Some patients do not benefit from the drug at all....

2011-09-07 19:57:00

Scientists at Dana-Farber Cancer Institute and colleagues overseas have discovered a pair of backup circuits in cancer cells that enable the cells to dodge the effect of a widely used cancer drug. Jamming those circuits with targeted therapies may heighten or restore the drug's potency, according to a study published in the Sept. 7 issue of Science Translational Medicine. The research focused on the drug cetuximab, an antibody that interferes with cancer cell growth by blocking a structure...

2011-09-01 12:54:27

Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed (brand name: Alimta) than patients whose cancer did not show ALK translocation, according to research published in the September issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer (IASLC). Lung adenocarcinoma can display genetic mutations, including anaplastic lymphoma kinase (ALK) rearrangement and...

2011-08-16 01:00:00

GERMANTOWN, Maryland and HILDEN, Germany, August 16, 2011 /PRNewswire/ -- - Diagnostic-therapeutic combination aims to improve standard of care for patients with non-small cell lung cancer (NSCLC) - Molecular test for KRAS gene mutations holds potential to help determine whether there is a subset of patients who are more likely to benefit from Pfizer's investigational anticancer compound - Collaboration in lung cancer...

2011-06-27 07:30:00

WALTHAM, Mass., June 27, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that data from two entinostat clinical trials both based on tumor reprogramming will be presented at the International Association for the Study of Lung Cancer's (IASLC) 14th World Conference on Lung Cancer meeting (www.2011worldlungcancer.org) July 3 to 7 in Amsterdam, The Netherlands. "The data presentations from both lung cancer programs at the...

2011-06-02 05:00:00

BOULDER, Colo., and PLEASANTON, Calif., June 2, 2011 /PRNewswire/ -- Clovis Oncology, Inc. and Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that they have entered into an agreement to develop an in vitro PCR (Polymerase Chain Reaction) based companion diagnostic test. The goal is to identify activating epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC), including the EGFR T790M mutation. "Once again we are able to demonstrate...

2011-06-01 15:06:28

Effect seen no matter how many drugs are given, analysis of 1975-2010 trial data shows Asian non-small cell lung cancer (NSCLC) patients survive longer than Caucasians no matter how many drugs are given in a first-line setting, and the effect was apparent both before and after the introduction of targeted therapies in the early 2000s, according to research published in the June issue of the Journal of Thoracic Oncology. "It is recognized Asian patients with a common type of lung cancer, the...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related